High prevalence of cancer is expected to positively shape the PARP-inhibitors market

 

PARP-inhibitors are widely used in the treatment of breast and prostate cancers. As an enzyme, polyamine resin and PARP-inhibitors belong to the class of lipid peroxidation inhibitors, which are used to combat cholesterol-fatigue and fatty deposits. These inhibitors also reduce triglyceride (fat) levels and improve insulin sensitivity.

The growing prevalence of cancer around the globe is a key factor driving the growth of the PARP inhibitor market. According to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Around 70% of deaths from cancer occur in low- and middle-income countries. Also, increasing spending on the healthcare sector for improving cancer treatment coupled with the growing prevalence of breast cancer and ovarian cancer among women is also projected to foster the growth of the PARP inhibitor biomarkers market. On the other hand, the high cost of PARP inhibitor biomarker test kits and assays is projected to hinder the growth of the PARP inhibitor market over the forecast period. 

 

North America is expected to exhibit significant growth over the forecast period and this is attributed to the high prevalence of cancer in the region. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths in the U.S.

Key Developments:

1. In May 2020, the Food and Drug Administration (FDA) expanded the approval of olaparib (Lynparza) for the initial treatment of women with advanced ovarian cancer

2. In April 2020, GlaxoSmithKline plc. announced that the US Food and Drug Administration (FDA) has approved the company’s supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube

3. In December 2019, AstraZeneca and MSD Inc., Kenilworth, N.J., US announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma

4. In October 2018, FDA approves a new PARP Inhibitor for BRCA-mutant breast cancer called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.